Fluticasone propionate
- Generic Name
- Fluticasone propionate
- Brand Names
- Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
- Drug Type
- Small Molecule
- Chemical Formula
- C25H31F3O5S
- CAS Number
- 80474-14-2
- Unique Ingredient Identifier
- O2GMZ0LF5W
- Background
Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
- Indication
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
- Associated Conditions
- Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
- Associated Therapies
- -
Biosimilar Market Trends: Drivers, Restraints and Growth Factors (2024)
The biosimilar market is growing due to increased development efforts, with FDA approving 40 biosimilars by December 2022. Despite a decline in approvals from 2020 to 2021, development programs are increasing, with 60-70 biosimilars in pipeline studies as of April 2023. However, market growth is restrained by lack of awareness and high treatment costs. Biosimilars offer a cost-effective alternative to biologics, with patent expirations creating opportunities for market expansion.
Overcoming barriers to patient adherence: the case for ...
The article discusses medication adherence challenges, highlighting the gap between clinical trial efficacy and real-world effectiveness, especially in chronic diseases like diabetes. It reviews strategies to improve adherence, including dosing frequency adjustments and novel drug delivery systems, emphasizing the importance of patient preferences and the impact of non-adherence on healthcare costs and outcomes.
GlaxoSmithKline to Plead Guilty and Pay $3 Billion for Unlawful Drug Promotion and Safety Data Failures
GlaxoSmithKline (GSK) agreed to a $3 billion settlement for unlawful promotion of drugs, failure to report safety data, and false price reporting. This includes $1 billion in criminal fines and $2 billion for civil liabilities, marking the largest healthcare fraud settlement in U.S. history.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath